There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seattle Genetics (SGEN) and Aduro BioTech (ADRO) with bullish sentiments.
Seattle Genetics (SGEN)
William Blair analyst Andy Hsieh maintained a Buy rating on Seattle Genetics yesterday. The company’s shares closed yesterday at $69.40.
According to TipRanks.com, Hsieh is a 1-star analyst with an average return of -1.9% and a 35.3% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Viking Therapeutics, and ImmunoGen.
Currently, the analyst consensus on Seattle Genetics is a Moderate Buy with an average price target of $76.71, implying a 10.5% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $98 price target.
See today’s analyst top recommended stocks >>
Aduro BioTech (ADRO)
William Blair analyst Matt Phipps maintained a Buy rating on Aduro BioTech on June 3. The company’s shares closed yesterday at $1.92, close to its 52-week low of $1.81.
According to TipRanks.com, Phipps has currently no stars on a ranking scale of 0-5 stars, with an average return of -21.2% and a 17.6% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics Plc, Atara Biotherapeutics, and Biogen Inc.
Aduro BioTech has an analyst consensus of Strong Buy, with a price target consensus of $8, a 316.7% upside from current levels. In a report issued on June 3, H.C. Wainwright also maintained a Buy rating on the stock with a $7 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.